Preventing contrast-related kidney injury in people hospitalized with acute heart failure
Official title: Contrast-Induced Acute Kidney Injury in Acute Heart Failure With Renal Dysfunction: The Kidney Protection Strategies Evaluation in Acute Heart Failure (K-PROSE)
Run by Seoul National University Bundang Hospital · NCT07550790 · Data updated 2026-11-12
This study tests whether a furosemide-based decongestion approach works better than standard IV saline to protect the kidneys of adults hospitalized with acute heart failure and moderate kidney dysfunction who need contrast scans.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 190 (estimated) |
| Sponsor | Seoul National University Bundang Hospital Academic / other |
| Locations | 1 site (Seongnam-si, Gyeonggi-do) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT07550790 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20 or older hospitalized for acute heart failure with clinical congestion, baseline eGFR 30–75 mL/min/1.73 m², and a planned contrast-enhanced CT during the admission are the intended participants.
✕Probably not a fit
Patients requiring vasopressors or renal replacement therapy, those with active acute coronary syndrome, severe electrolyte disturbances or volume depletion, pregnant or breastfeeding women, or anyone with a furosemide allergy would not be expected to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The K-PROSE study enrolls adults hospitalized with acute heart failure, clinical evidence of congestion, and baseline eGFR 30–75 mL/min/1.73 m² who require contrast-enhanced CT imaging. Participants are randomized to receive either standard intravenous isotonic saline hydration or a furosemide-based decongestion protocol before and after contrast exposure. Renal function is monitored with serial measurements of serum creatinine, eGFR, and cystatin C, and outcomes include incidence of contrast-induced acute kidney injury, changes in congestion status, and safety events. The trial is designed to reflect real-world acute care while systematically comparing renal and clinical outcomes between the two strategies.
Why it matters
Potential benefit: If successful, this approach could reduce contrast-induced kidney injury and its complications in high-risk acute heart failure patients, potentially lowering the need for dialysis and shortening hospital stays.
How similar studies have gone: While IV saline hydration has been shown to reduce CI-AKI risk in broader populations, applying a furosemide-based decongestion strategy specifically in acute heart failure is relatively novel and supported by limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 20 years or older * Emergency department visit/hospitalization for acute heart failure with clinical evidence of congestion * Planned contrast-enhanced computed tomography during the index hospitalization * Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL/min/1.73 m² Exclusion Criteria: * Requirement for vasopressor therapy * Requirement for renal replacement therapy (dialysis) * Known allergy or hypersensitivity to furosemide * Ongoing acute coronary syndrome * Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test * Hyperkalemia (serum potassium \>5.5 mmol/L) * Uncorrected volume depletion or hyponatremia (serum sodium \<130 mmol/L) * Any condition deemed by the investigator to make participation in the study inappropriate
Where it's running
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea Recruiting
Study contacts
- Principal investigator: Jin Joo Park, MD, PhD — Seoul National University Bundang Hospital
- Study coordinator: Jin Joo Park, MD, PhD
- Email: jinjooparkmd@snubh.org
- Phone: +82-031-787-8800
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care
This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
Lung ultrasound and lactate at discharge to predict 30-day outcomes after acute heart failure
We’re testing whether a combination of lung ultrasound and blood lactate at discharge can help predict who will be readmitted or die within 30 days after leaving the hospital for acute heart failure.
-
Using urine sodium to guide IV diuretic dosing for hospitalized acute heart failure
This trial will test whether increasing IV diuretic doses to reach higher urine sodium levels helps hospitalized adults with acute decompensated heart failure remove more salt and fluid and have fewer readmissions.
-
Finding hidden early heart failure in at-risk adults in major German cities using mobile MRI
This project will test whether a mobile, telemedicine‑supervised screening using cardiac MRI, lab tests, and questionnaires can find hidden (asymptomatic) heart failure in adults aged 40–69 with heart risk factors living in large German cities.
-
Cardiac point-of-care ultrasound training pathway for emergency advanced practice providers
This project will test a simulation-based and just-in-time training program to teach emergency department nurse practitioners and physician assistants to perform focused cardiac POCUS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.